Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma
| Autor: | Zehra Yasar, Celalettin Ibrahim Kocaturk, Esin Tuncay, Zehra Dilek Kanmaz, Buge Oz, Cihan Gündoğan, Canan Ünlü Özkurt, Gülfidan Aras, Ayse Bahadir, Tevfik Fikret Çermik |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Thyroid Nuclear Factor 1 Mutant Standardized uptake value 03 medical and health sciences 0302 clinical medicine Internal medicine Genetics medicine Lung cancer Lung business.industry Retrospective cohort study General Medicine respiratory system medicine.disease 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Mutation (genetic algorithm) Adenocarcinoma Radiology business |
| Zdroj: | Cancer Biomarkers. 16:489-498 |
| ISSN: | 1875-8592 1574-0153 |
| DOI: | 10.3233/cbm-160588 |
| Popis: | Aim The aim of this study is to evaluate the diagnostic value of PET-CT scan for the prediction of EGFR mutation status and the contribution of TTF-1 expression to PET-CT scan. Methods We retrospectively studied 218 cases with a diagnosis of pulmonary adenocarcinoma between 2012-2014 which underwent EGFR analysis, TTF-1 and PET-CT before treatment. Results The EGFR mutation was present in 28.9% (n= 63) of cases. TTF-1 positivity was 66.9% (n= 105). Standardized uptake value (SUV max) was 16.7 ± 6.8 in EGFR mutant type, 13.8 ± 7.6 in cases having no EGFR mutations. According to our evaluations, high SUVmax is positively correlated with EGFR mutation status. TTF-1 expression in multivariate analysis strengthens the accuracy of detecting an EGFR mutation. Conclusion PET-CT FDG uptake may, together with TTF-1 expression, help diagnosis in lung adenocarcinoma cases when evaluating for EGFR mutation status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|